v3.25.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jul. 31, 2025
Oct. 31, 2024
Current assets:    
Cash and cash equivalents $ 1,495 $ 1,271
Short-term investments 14,534 18,653
Receivables 173
Prepaid expenses and other current assets 1,420 1,265
Total current assets 17,449 21,362
Operating lease right-of-use asset 202 229
Total assets 17,651 21,591
Current liabilities:    
Accounts payable 276 525
Accrued expenses 1,751 1,946
Operating lease liability, current 39 29
Total current liabilities 2,066 2,500
Operating lease liability, non-current 174 203
Total liabilities 2,240 2,703
Commitments and contingencies (Note 10)
Shareholders’ equity:    
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 32,822,109 and 32,196,862 shares issued and outstanding as of July 31, 2025 and October 31, 2024, respectively 328 322
Additional paid-in capital 265,249 260,432
Accumulated deficit (248,982) (240,750)
Treasury stock, 2,000 shares at cost as of October 31, 2024 (6)
Total shareholders’ equity 16,595 19,998
Noncontrolling interest (Note 2) (1,184) (1,110)
Total equity 15,411 18,888
Total liabilities and equity 17,651 21,591
Series A Convertible Preferred Stock [Member]    
Shareholders’ equity:    
Preferred stock, value

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2025
Jul. 31, 2024
Income Statement [Abstract]        
Revenue
Operating expenses:        
Research and development expenses (including non-cash stock-based compensation expenses of $358, $462, $1,172 and $1,471, respectively) 1,055 1,925 3,929 4,920
General and administrative expenses (including non-cash stock-based compensation expenses of $497, $717, $1,727 and $2,228, respectively) 1,381 1,667 4,896 5,748
Total operating expenses 2,436 3,592 8,825 10,668
Loss from operations (2,436) (3,592) (8,825) (10,668)
Interest income 156 277 519 883
Net loss (2,280) (3,315) (8,306) (9,785)
Less: Net loss attributable to noncontrolling interest (22) (38) (74) (114)
Net loss attributable to common shareholders $ (2,258) $ (3,277) $ (8,232) $ (9,671)
Net loss per common share attributable to common shareholders:        
Basic $ (0.07) $ (0.10) $ (0.25) $ (0.30)
Diluted $ (0.07) $ (0.10) $ (0.25) $ (0.30)
Weighted average common shares outstanding:        
Basic 32,476 32,054 32,293 31,804
Diluted 32,476 32,054 32,293 31,804

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (8,306) $ (9,785)
Stock option compensation to employees and directors 2,822 3,440
Stock options issued to consultants 77 101
Common stock issued to consultants 255
Amortization of operating lease right-of-use asset 27 28
Amortization of discount on held-to-maturity securities (93)
Change in operating assets and liabilities:    
Receivables 173 (140)
Prepaid expenses and other current assets (155) (273)
Accounts payable (249) 96
Accrued expenses (195) (92)
Operating lease liability (19) (38)
Net cash used in operating activities (5,918) (6,408)
Cash flows from investing activities:    
Disbursements to acquire short-term investments (36,700) (47,307)
Proceeds from maturities of short-term investments 40,912 50,716
Net cash provided by investing activities 4,212 3,409
Cash flows from financing activities:    
Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $123 and $139, respectively 1,924 2,984
Proceeds from sale of common stock pursuant to an employee stock purchase plan 4 7
Proceeds from exercise of stock options 2 318
Net cash provided by financing activities 1,930 3,309
Net increase in cash and cash equivalents 224 310
Cash and cash equivalents at beginning of period 1,271 915
Cash and cash equivalents at end of period 1,495 1,225
Supplemental disclosure of non-cash investing activity:    
Operating lease right-of-use asset from lease extension (100)
Supplemental disclosure of non-cash financing activity:    
Operating lease liability from lease extension $ 100

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL